卵巢癌的树突状细胞疫苗研究现状及展望

Research status and prospect in dendritic cell vaccine for ovarian cancer

卵巢癌在妇科恶性肿瘤中病死率最高,现有的治疗方法仍难以根治。树突状细胞(DCs)是机体内的专职性抗原递呈细胞,能显著刺激初始型T细胞增殖,因此在免疫反应中具有独特的作用。近年来,利用DCs疫苗进行抗卵巢癌治疗已成为卵巢癌免疫治疗的热点之一。该文综述了卵巢癌DCs疫苗的研究进展,包括DCs对肿瘤的作用机制、疫苗的制备方法、临床试验以及目前该项技术的局限性及其未来的展望。

Ovarian cancer has the highest fatality rate among gynecological cancers. Currently, radical treatment is not yet available. Dendritic ceils （ DCs）, whose sole duty is antigen-presenting, can significantly stimulate the proliferation of naive T cells, thus playing a unique role in immune reaction. Recently, anti-ovarian cancer treatment using DCs vaccine has become one of the hot spots in immunotherapy. This paper reviews the current status of DCs vaccine research, including the preparation and clinical trials of the vaccines, mechanism of DCs affecting carcinoma, and the imperfectness and prospect of this technology.